SOPHIRIS BIO (SPHS) Covered Calls

You can sell covered calls on SOPHIRIS BIO to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for SPHS (prices last updated Mon 4:16 PM ET):

SOPHIRIS BIO (SPHS) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
2.44 +0.05 2.40 2.46 77K - 0.1B
Covered Calls For SOPHIRIS BIO (SPHS)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Sep 21 2.5 0.05 2.41 2.1% 23.2%
Oct 19 2.5 0.40 2.06 19.4% 116%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 and other products for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. Sophiris Bio, Inc. was founded in 2002 and is based in La Jolla, California.